GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: compound A-1 [WO2022023450]
Compound class:
Synthetic organic
Comment: The chemical structure for flezurafenib was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a rapidly accelerated fibrosarcoma (Raf) kinase inhibitor with proposed antineoplastic action. It is one of the Raf inhibitors claimed in patent WO2022023450A1 [1]. Investigation of Jazz Pharmaceuticals' pipeline suggests that flezurafenib may be their oral pan-Raf inhibitor clinical lead JZP815. This lead is being explored for efficacy against solid tumours and haematologic malignancies harbouring oncogenic mutations that activate the RAS-RAF-MAPK pathway. We will update this entry when the structure for flezurafenib or JZP815 is publicly disclosed.
|
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
IUPAC Name ![]() |
| 5-[[(3S)-3-[5-(4-fluorophenyl)-1H-imidazol-2-yl]-3,4-dihydro-2H-chromen-6-yl]oxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 12891 | flezurafenib |
Synonyms ![]() |
| compound A-1 [WO2022023450] |
Database Links ![]() |
|
| CAS Registry No. | 2760321-00-2 (source: WHO INN record) |
| GtoPdb PubChem SID | 491300015 |
| PubChem CID | 162772363 |
| Search Google for chemical match using the InChIKey | TWJSMWXWCWQPRO-QGZVFWFLSA-N |
| Search Google for chemicals with the same backbone | TWJSMWXWCWQPRO |
| Search PubMed clinical trials | flezurafenib |
| Search PubMed titles | flezurafenib |
| Search PubMed titles/abstracts | flezurafenib |
| UniChem Compound Search for chemical match using the InChIKey | TWJSMWXWCWQPRO-QGZVFWFLSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | TWJSMWXWCWQPRO-QGZVFWFLSA-N |